Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ODT2 Test formulation
ODT #2 with water · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1 | EXPERIMENTAL | - |
| Treatment Sequence 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ODT2 Test formulation | DRUG | Test Formulation |
| ODT Reference formulation | DRUG | Reference Formulation |
Inclusion Criteria: 1. Male or female participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs. 2. Hav...
Top 5 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 11 | PHASE3 | Rimegepant, Zavegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
ODT #2 with water is an investigational small molecule formulation being developed by Pfizer, Inc. for migraine. It is an orally disintegrating tablet formulation studied in a Phase 1 clinical trial comparing blood levels of two dosage formulations of the study medicine in healthy adults.
ODT #2 with water is being studied for migraine, which falls within the neurology therapeutic area. The completed Phase 1 trial enrolled healthy adult volunteers rather than migraine patients, so the study evaluated the formulation in healthy participants.
Pfizer, Inc. is the developer of ODT #2 with water. Pfizer trades on the New York Stock Exchange under the ticker symbol PFE.
ODT #2 with water is in Phase 1 clinical development. It is an investigational formulation and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
ODT #2 with water has been studied in one completed Phase 1 trial, NCT07594769, titled A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults. The trial enrolled 36 healthy adults in Belgium and was randomized and controlled.
Yes, ODT #2 with water is also known as ODT2 Test formulation. Both names refer to the same Pfizer investigational small molecule formulation studied for migraine in the completed Phase 1 trial NCT07594769.